---
layout: post
title: "疫苗质量堪忧八成遭退货？台湾高端斥不实信息"
date: 2021-07-23T09:40:19.318Z
author: 联合早报
from: https://www.zaobao.com/realtime/china/story20210723-1172637
tags: [ 联合早报 ]
categories: [ 联合早报 ]
---
<!--1627052940000-->
[疫苗质量堪忧八成遭退货？台湾高端斥不实信息](https://www.zaobao.com/realtime/china/story20210723-1172637)
------

<div>
<p>针对市场传出台湾高端“产能规模只有8.8万剂”、“抗原品质偏差大”、“疫苗超过八成遭退货，产品质量堪忧”等信息，高端今天发布声明澄清，指上述信息不实，吁请媒体勿用不明来源信息进行不实报道。<br> <br>根据台湾《经济日报》报道，高端在声明中说，疫苗从关键原物料生产、到检测放行，不但规格严谨、项目繁多、且耗时长。从最前端的入料检验、制程中管控、到最终端成品放行，须完成超过百项严谨检验，始可放行。</p><p>声明说，目前公司抗原产能远高于媒体报道臆测的数值，抗原库存量也大于目前台湾采购规划的500万目标数量，且均符合放行规格。后续将按供货时程进行疫苗成品充填出货。所有疫苗成品皆会100%符合规格，并在完成厂内放行与食药署研检封缄程序后释出。</p><p>声明说，疫苗工厂生产必须遵守相关规范，透过严格验证过程与标准，以确保产品品质。媒体臆测有关生产良率及每批产能等数字全然错误，请非疫苗生产专业之人士，勿以来路不明、内容不符现况的资讯，进行不实陈述，意图影响台湾人对台湾产疫苗信心。</p><section id="imu"><div id="dfp-ad-imu1">        </div></section>      <div id="innity-in-post"></div><div id="dfp-ad-midarticlespecial">        </div>      <a href="https://subscribe.sph.com.sg/promotions/chinese-3-months-99-cents-promotion/?utm_campaign=cn3in199c&utm_medium=sph-publication&utm_source=zb&utm_content=subscribelink-free-endofarticle" target="_blank"><img class="view-desktop lazyload  " data-src="https://static.zaobao.com/s3fs-public/freemium_images/20210209/399-default-desktop-l_0_1.jpg" alt style="width:100%;" pinger-seen="true" src="https://static.zaobao.com/s3fs-public/freemium_images/20210209/399-default-desktop-l_0_1.jpg" referrerpolicy="no-referrer"></a>      <a href="https://subscribe.sph.com.sg/promotions/chinese-3-months-99-cents-promotion/?utm_campaign=cn3in199c&utm_medium=sph-publication&utm_source=zb&utm_content=subscribelink-free-endofarticle" target="_blank"><img class="view-mobile lazyload " data-src="https://static.zaobao.com/s3fs-public/freemium_images/20210209/399-default-mobile_1.jpg" alt pinger-seen="true" src="https://static.zaobao.com/s3fs-public/freemium_images/20210209/399-default-mobile_1.jpg" referrerpolicy="no-referrer"></a>
</div>
